Diurnal Group plc £20m fundraise success

News

We are very pleased to have acted as Nomad, Sole Broker and Sole Bookrunner for the successful £20m fundraising for Diurnal Group plc.

Diurnal is a European, UK-headquartered pharmaceutical company dedicated to developing hormone therapeutics to aid lifelong treatment for rare and chronic endocrine conditions.

The net proceeds of the fundraise will be used to progress the pivotal Phase 3 studies of Efmody® in the US through to registration in congenital adrenal hyperplasia (CAH) and the continued support of the evolution of the Group’s earlier stage pipeline.

Diurnal Group plc £20m fundraise success

Other insights like this

Boohoo might not return to profit until 2026, analysts warn

Bed down with this well-run growth stock

6 VCTs appoint Panmure Gordon

Women in Research event

Close Brothers in a close shave

Acted as Rule 3 Adviser, Financial Adviser, Nominated Adviser and Sole Broker

UK Inflation May Fall Faster Than Expected

Ebiquity plc – Panmure Gordon acted as Financial Adviser, Nominated Adviser, Broker and Bookrunner